Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 2/20 | 0.62 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081461 | 0.86 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL4224867 | 0.86 | NPC1 (0.60) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2083034 | 0.85 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL4299075 | 0.84 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2082517 | 0.84 | MAP3K7 (0.66) | MAP3K7TAB1MAPK14MAPK13MAPK12 | |
| SCHEMBL2082979 | 0.83 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2081660 | 0.83 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2082310 | 0.83 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2082582 | 0.83 | MAPK14 (0.76) | MAP3K7MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2082943 | 0.83 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MAP3K7 59/4885TAB1 935/4885MAPK14 80/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAP3K7 10/4885TAB1 340/4885MAPK14 29/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MAP3K7 63/4885TAB1 1037/4885MAPK14 128/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MAP3K7 22/4885TAB1 240/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.